[1]
|
Mandruzzato, G., Antsaklis, A., Botet, F., Chervenak, F.A., Figueras, F., Grunebaum, A., Puerto, B., Skupski, D. and Stanojevic, M. (2008) Intrauterine restriction (IUGR). Journal of Perinatal Medicine, 36, 277-281.
doi:10.1515/JPM.2008.050
|
[2]
|
Maynard, S.E., Min, J.Y., Merchan, J., Lim, K.H., Li, J., Mondal, S., Libermann, T.A., Morgan, J.P., Selke, F.W., Stillman, I.E., Epstein, F.H., Sukhatme, V.P.M. and Karumanchi, S.A. (2003) Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. Journal of Clinical Investigation, 111, 600-602.
|
[3]
|
Marsal, K. (2002) Intrauterine growth restriction. Current Opinion in Obstetrics and Gynecology, 14,127-135.
doi:10.1097/00001703-200204000-00005
|
[4]
|
Robinson, J.S. and Owens, J.A. (1996) Pathophysiology of intrauterine growth failure. In: Gluckman, P.D. and Heymann, M.A., Eds., Pediatrics and Perinatology: The Scientific Basis, Arnold, London, 290-297.
|
[5]
|
Bretelle, F., Sabatier, F., Blann, A., D’Ercole, Boutiere, B., Mutin, M., Boubli, L., Sampol, J. and Dignat-George, F. (2001) Maternal endothelial soluble cell adhesion molecules with isolated small for gestational age fetuses, comparison with preeclampsia. British Journal of Obstetrics Gynaecology, 108, 1277-1282.
doi:10.1016/S0306-5456(01)00259-5
|
[6]
|
Bamberger, A.M., Schulte, H.M., Thuneke, I., Erdmann, I., Bamberger, ChM. and Asa, S.L. (1997) Expression of the apoptosis-inducing fas ligand (FasL) in human first and third trimester placenta and choriocarcinoma cells. Journal of Clinical Endocrinology & Metabolism, 82, 3173-3175. doi:10.1210/jc.82.9.3173
|
[7]
|
Hsu, ChD., hariah, H., Basherra, H. and Mor, A.G. (2001) Serum soluble fas levels in preeclampsia. Obstetrics and Gynecology, 97, 530-532.
doi:10.1016/S0029-7844(00)01227-8
|
[8]
|
Roberts, J.M. (1999) Objective evidence of endothelial dysfunction in preeclampsia. American Journal of Kidney Diseases, 33, 992-997.
doi:10.1016/S0272-6386(99)70439-7
|
[9]
|
Granger, J.P., Alexander, B.T., Llinas, M.T., Bennett, W.A. and Khalil, R.A. (2001) Pathophysiology of hypertension during preeclampsia linking placental ischemia with endothelial dysfunction. Hypertension, 38, 718-722.
|
[10]
|
Kassab, S., Abu-Hijleh, M.F., Al-Shaikh, H.B. and Nagalla, D.S. (2005) Hyperhomocysteinemia in pregnant rats: Effects on arterial pressure, kidneys and fetal growth. European Journal of Obstetrics & Gynecology and Reproductive, 122, 177-181.
doi:10.1016/j.ejogrb.2005.02.008
|
[11]
|
Aubard, Y., Darodes, N. and Cantaloube, M. (2000) Hyperhomocysteinemia and pregnancy—review of our present understanding and therapeutic implications. European Journal of Obstetrics & Gynecology and Reproductive, 93, 57-165.
|
[12]
|
Onalan, R., Onalan, G., Gunenc, Z. and Karabulut, E. (2006) Combining 2nd trimester maternal serum homocysteine levels and uterine artery doppler for prediction of preeclampsia and isolated intrauterine growth restriction. Gynecology and Obstetrics Investigaton, 61, 142- 148. doi:10.1159/000090432
|
[13]
|
Weir, D.G. and Scott, J.M. (1998) Homocysteine as a risk factor for cardiovascular and related disease: Nutritional implications. Nutrition Research Reviews, 11, 311-338.
doi:10.1079/NRR19980020
|
[14]
|
López-Quesada, E., Also-Razo, E. and Vilaseca, M.A. (2003) Hyperhomocysteinemia during pregnancy as a risk factor of preeclampsia. Clinical Medicine, 121, 350-355.
|
[15]
|
Wang, J., Trudinger, B.J., Duarte, N., Wilcken, D.E. and Wang, X.L. (2000) Elevated circulating homocysteine levels in placental vascular disease and associated pre-eclampsia. British Journal of Obstetrics and Gynaecology, 107, 935-938.
doi:10.1111/j.1471-0528.2000.tb11095.x
|
[16]
|
Mao, D., Che, J., Li, K., Han, S., Yue, Q., Zhu, L., Zhang, W. and Li, L. (2009) Association of homocysteine, asymmetric dimethylarginine, and nitric oxide with preeclampsia. Archives of Gynecology and Obstetrics, 1234-1236.
|
[17]
|
De Falco, M., Pollio, F., Scaramelino, M., Portillo, M. and Lieto, A.D. (2000) Homocysteinemia during pregnancy and placental disease. Clinical & Experimental Obstetrics & Gynecology, 27, 188-190.
|
[18]
|
Steegers-Theunissen, R.P., Van Iersel, C.A., Peer, P.G., Nelen, W.L. and Steegers, E.A. (2004) Hyperhomocysteinemia, pregnancy complications, and the timing of investigation. Obstetrics and Gynecology, 104, 336-343.
doi:10.1097/01.AOG.0000129955.47943.2a
|
[19]
|
Lindblad, B., Zaman, S., Malik, A., Martin, H., Ekstr?m, A.M., Amu, S., Holmgren, A. and Norman, M. (2005) Folate, vitamin B12 and homocysteine levels in South Asian women with growth-retarded fetuses. Acta Obstetricia et Gynecologica Scandinavica, 84, 1055-1061.
|
[20]
|
Infante-Rivard, C., Rivard, G.E., Gauthier, R. and Théoret, Y. (2003) Unexpected relationship between pla- sma homocysteine and intrauterine growth restriction. Clinical Chemistry, 49, 1476-1482.
doi:10.1373/49.9.1476
|
[21]
|
Hogg, ChD., Harirah, H., Basherra, H. and Mor, A.G. (2001) Serum soluble fas levels in preeclampsia. Obstetrics and Gynecology, 97, 530-532.
doi:10.1016/S0029-7844(00)01227-8
|
[22]
|
D’Anna, R., Bariera, G., Corrido, F., Lentile, R., Granese, D. and Stella, N.C. (2004) Plasma homocysteine in early and late pregnancies complicated with preeclampsia and isolated intrauterine growth restriction. Acta Obstetricia et Gynecologica Scandinavica, 83, 155-158.
|